Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2021

05.04.2021 | Gynecologic Oncology

Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer

verfasst von: Kana Tanaka, MD, Yoshifumi Shimada, MD, PhD, Koji Nishino, MD, PhD, Kosuke Yoshihara, MD, PhD, Masato Nakano, MD, PhD, Hitoshi Kameyama, MD, PhD, Takayuki Enomoto, MD, PhD, Toshifumi Wakai, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Mesenteric lymph node (MLN) involvement is often observed in ovarian cancer (OC) with rectosigmoid invasion. This study aimed to investigate the clinical significance of MLN involvement in the pattern of liver metastasis in patients with OC.

Methods

We included 85 stage II–IV OC patients who underwent primary or interval debulking surgery. Twenty-seven patients underwent rectosigmoid resection, whose status of MLN involvement was judged from hematoxylin and eosin (H&E) staining of resected specimens. The prognostic significance of clinicopathological characteristics, including MLN involvement, was evaluated using univariate and multivariate analyses.

Results

MLN involvement was detected in 14/85 patients with stage II–IV OC. Residual tumor status, cytology of ascites, and MLN involvement were independent prognostic factors for progression-free survival (PFS; p = 0.033, p = 0.014, and p = 0.008, respectively). When patients were classified into three groups (no MLN, one MLN, two or more MLNs), the number of MLNs involved corresponded to three distinct groups in PFS (p = 0.001). The 3-year cumulative incidence of liver metastasis of patients with MLN involvement was significantly higher than that of patients without MLN involvement (61.1% vs. 8.9%, p < 0.001). MLN involvement was significantly associated with liver metastasis of hematogenous origin (p < 0.001) compared with peritoneal disseminated origin.

Conclusion

MLN involvement is an important prognostic factor in OC, predicting poor prognosis and liver metastasis of hematogenous origin.
Literatur
1.
Zurück zum Zitat Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef
2.
Zurück zum Zitat Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.PubMedCrossRef Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278–87.PubMedCrossRef
3.
Zurück zum Zitat Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol. 2001;82:435–41.PubMedCrossRef Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: Is there a correlation with “biological aggressiveness” and survival? Gynecol Oncol. 2001;82:435–41.PubMedCrossRef
4.
Zurück zum Zitat Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol Oncol. 2013;130:493–8.PubMedCrossRef Chang SJ, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: A meta-analysis. Gynecol Oncol. 2013;130:493–8.PubMedCrossRef
5.
Zurück zum Zitat Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000;88:389–97.PubMedCrossRef Scarabelli C, Gallo A, Franceschi S, et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer. 2000;88:389–97.PubMedCrossRef
6.
Zurück zum Zitat Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2001;83:286–91.PubMedCrossRef Jaeger W, Ackermann S, Kessler H, Katalinic A, Lang N. The effect of bowel resection on survival in advanced epithelial ovarian cancer. Gynecol Oncol. 2001;83:286–91.PubMedCrossRef
7.
Zurück zum Zitat Obermair A, Hagenauer S, Tamandl D, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83:115–20.PubMedCrossRef Obermair A, Hagenauer S, Tamandl D, et al. Safety and efficacy of low anterior en bloc resection as part of cytoreductive surgery for patients with ovarian cancer. Gynecol Oncol. 2001;83:115–20.PubMedCrossRef
8.
Zurück zum Zitat Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608–14.PubMedCrossRef Mourton SM, Temple LK, Abu-Rustum NR, et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 2005;99:608–14.PubMedCrossRef
9.
Zurück zum Zitat Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006;203:521–6.PubMedCrossRef Aletti GD, Podratz KC, Jones MB, Cliby WA. Role of rectosigmoidectomy and stripping of pelvic peritoneum in outcomes of patients with advanced ovarian cancer. J Am Coll Surg. 2006;203:521–6.PubMedCrossRef
10.
Zurück zum Zitat Estes JM, Leath CA 3rd, Straughn JM Jr, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203:527–32.PubMedCrossRef Estes JM, Leath CA 3rd, Straughn JM Jr, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg. 2006;203:527–32.PubMedCrossRef
11.
Zurück zum Zitat Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103:977–84.PubMedCrossRef Park JY, Seo SS, Kang S, et al. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns. Gynecol Oncol. 2006;103:977–84.PubMedCrossRef
12.
Zurück zum Zitat Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667–72.PubMedCrossRef Richardson DL, Mariani A, Cliby WA. Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol. 2006;103:667–72.PubMedCrossRef
13.
Zurück zum Zitat Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107:495–9.PubMedCrossRef Salani R, Zahurak ML, Santillan A, Giuntoli RL 2nd, Bristow RE. Survival impact of multiple bowel resections in patients undergoing primary cytoreductive surgery for advanced ovarian cancer: a case-control study. Gynecol Oncol. 2007;107:495–9.PubMedCrossRef
14.
Zurück zum Zitat Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126:220–3.PubMedCrossRef Peiretti M, Bristow RE, Zapardiel I, et al. Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol. 2012;126:220–3.PubMedCrossRef
15.
Zurück zum Zitat Giorda G, Gadducci A, Lucia E, et al. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. J Ovarian Res. 2014;7:72.PubMedPubMedCentralCrossRef Giorda G, Gadducci A, Lucia E, et al. Prognostic role of bowel involvement in optimally cytoreduced advanced ovarian cancer: a retrospective study. J Ovarian Res. 2014;7:72.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Derlatka P, Sienko J, Grabowska-Derlatka L, et al. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol. 2016;14:58.PubMedPubMedCentralCrossRef Derlatka P, Sienko J, Grabowska-Derlatka L, et al. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer. World J Surg Oncol. 2016;14:58.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Philip CA, Pelissier A, Bonneau C, Hequet D, Rouzier R, Pouget N. Impact of neoadjuvant chemotherapy on the rate of bowel resection in advanced epithelial ovarian cancer. Anticancer Res. 2016;36:4865–71.PubMedCrossRef Philip CA, Pelissier A, Bonneau C, Hequet D, Rouzier R, Pouget N. Impact of neoadjuvant chemotherapy on the rate of bowel resection in advanced epithelial ovarian cancer. Anticancer Res. 2016;36:4865–71.PubMedCrossRef
18.
Zurück zum Zitat Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. Eur J Surg Oncol. 2016;42:383–90.PubMedCrossRef Plotti F, Montera R, Aloisi A, et al. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer. Eur J Surg Oncol. 2016;42:383–90.PubMedCrossRef
19.
Zurück zum Zitat Kim M, Suh DH, Park JY, et al. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol. 2018;29:e60.PubMedPubMedCentralCrossRef Kim M, Suh DH, Park JY, et al. Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol. 2018;29:e60.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30:e25.PubMedCrossRef Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30:e25.PubMedCrossRef
21.
Zurück zum Zitat O’Hanlan KA, Kargas S, Schreiber M, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995;59:200–6.PubMedCrossRef O’Hanlan KA, Kargas S, Schreiber M, et al. Ovarian carcinoma metastases to gastrointestinal tract appear to spread like colon carcinoma: implications for surgical resection. Gynecol Oncol. 1995;59:200–6.PubMedCrossRef
22.
Zurück zum Zitat Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007;14:3552–7.PubMedCrossRef Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol. 2007;14:3552–7.PubMedCrossRef
23.
Zurück zum Zitat Baiocchi G, Cestari LA, Macedo MP, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011;104:250–4.PubMedCrossRef Baiocchi G, Cestari LA, Macedo MP, et al. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection. J Surg Oncol. 2011;104:250–4.PubMedCrossRef
24.
Zurück zum Zitat Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012;38:170–5.PubMedCrossRef Gouy S, Goetgheluck J, Uzan C, Duclos J, Duvillard P, Morice P. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer. Eur J Surg Oncol. 2012;38:170–5.PubMedCrossRef
25.
Zurück zum Zitat Di Giorgio A, Cardi M, Biacchi D, et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol. 2013;11:64.PubMedPubMedCentralCrossRef Di Giorgio A, Cardi M, Biacchi D, et al. Depth of colorectal-wall invasion and lymph-node involvement as major outcome factors influencing surgical strategy in patients with advanced and recurrent ovarian cancer with diffuse peritoneal metastases. World J Surg Oncol. 2013;11:64.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Kumagai K, Okamura T, Toyoda M, Senzaki H, Watanabe C, Ohmichi M. Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET/CT in treatment planning. World J Surg Oncol. 2013;11:184.PubMedPubMedCentralCrossRef Kumagai K, Okamura T, Toyoda M, Senzaki H, Watanabe C, Ohmichi M. Rectal lymph node metastasis in recurrent ovarian carcinoma: essential role of 18F-FDG PET/CT in treatment planning. World J Surg Oncol. 2013;11:184.PubMedPubMedCentralCrossRef
27.
Zurück zum Zitat Gallotta V, Fanfani F, Fagotti A, et al. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations. Ann Surg Oncol. 2014;21:2369–75.PubMedCrossRef Gallotta V, Fanfani F, Fagotti A, et al. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations. Ann Surg Oncol. 2014;21:2369–75.PubMedCrossRef
28.
Zurück zum Zitat Berretta R, Capozzi VA, Sozzi G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer. Arch Gynecol Obstet. 2018;297:997–1004.PubMedCrossRef Berretta R, Capozzi VA, Sozzi G, et al. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer. Arch Gynecol Obstet. 2018;297:997–1004.PubMedCrossRef
29.
Zurück zum Zitat Amin MB, Edge S, Greene F, et al editors. AJCC cancer staging manual. 8th edn. New York: Springer International; 2017. Amin MB, Edge S, Greene F, et al editors. AJCC cancer staging manual. 8th edn. New York: Springer International; 2017.
31.
Zurück zum Zitat Lim MC, Kang S, Lee KS, et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 2009;112:28–34.PubMedCrossRef Lim MC, Kang S, Lee KS, et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 2009;112:28–34.PubMedCrossRef
32.
Zurück zum Zitat O’Neill AC, Somarouthu B, Tirumani SH, et al. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer: a single-institution experience with 244 patients. Radiology. 2017;282:160–70.PubMedCrossRef O’Neill AC, Somarouthu B, Tirumani SH, et al. Patterns and prognostic importance of hepatic involvement in patients with serous ovarian cancer: a single-institution experience with 244 patients. Radiology. 2017;282:160–70.PubMedCrossRef
33.
Zurück zum Zitat Chi DS, Temkin SM, Abu-Rustum NR, Sabbatini P, Jarnagin WR, Blumgart LH. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol. 2002;87:138–42.PubMedCrossRef Chi DS, Temkin SM, Abu-Rustum NR, Sabbatini P, Jarnagin WR, Blumgart LH. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: a case report. Gynecol Oncol. 2002;87:138–42.PubMedCrossRef
34.
Zurück zum Zitat Lee JH, Kim KS, Chung CW, Park YN, Kim BR. Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. J Korean Med Sci. 2002;17:415–8.PubMedPubMedCentralCrossRef Lee JH, Kim KS, Chung CW, Park YN, Kim BR. Hepatic resection of metastatic tumor from serous cystadenocarcinoma of the ovary. J Korean Med Sci. 2002;17:415–8.PubMedPubMedCentralCrossRef
35.
Zurück zum Zitat Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16–21.PubMedCrossRef Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16–21.PubMedCrossRef
36.
Zurück zum Zitat Bacalbasa N, Dima S, Brasoveanu V, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol. 2015;13:235.PubMedPubMedCentralCrossRef Bacalbasa N, Dima S, Brasoveanu V, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol. 2015;13:235.PubMedPubMedCentralCrossRef
38.
Zurück zum Zitat Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.PubMedCrossRef Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.PubMedCrossRef
39.
Zurück zum Zitat Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.PubMedCrossRef Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.PubMedCrossRef
40.
Zurück zum Zitat Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36.PubMedPubMedCentralCrossRef Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928–36.PubMedPubMedCentralCrossRef
41.
Zurück zum Zitat Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317–28.PubMedPubMedCentralCrossRef Tewari KS, Burger RA, Enserro D, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317–28.PubMedPubMedCentralCrossRef
42.
Zurück zum Zitat Rinderknecht M, Detmar M. Molecular mechanisms of lymph node metastasis. In: Stacker SA, Achen MG, editors. Lymphangiogenesis in cancer metastasis: cancer metastasis—biology and treatment 13. Dordrecht: Springer; 2009. p. 55–82.CrossRef Rinderknecht M, Detmar M. Molecular mechanisms of lymph node metastasis. In: Stacker SA, Achen MG, editors. Lymphangiogenesis in cancer metastasis: cancer metastasis—biology and treatment 13. Dordrecht: Springer; 2009. p. 55–82.CrossRef
43.
Zurück zum Zitat Kumar V, Abbas AK, Aster JC. Robbins basic pathology. 10th edn. Pennsylvania: Elsevier; 2019. Kumar V, Abbas AK, Aster JC. Robbins basic pathology. 10th edn. Pennsylvania: Elsevier; 2019.
Metadaten
Titel
Clinical Significance of Mesenteric Lymph Node Involvement in the Pattern of Liver Metastasis in Patients with Ovarian Cancer
verfasst von
Kana Tanaka, MD
Yoshifumi Shimada, MD, PhD
Koji Nishino, MD, PhD
Kosuke Yoshihara, MD, PhD
Masato Nakano, MD, PhD
Hitoshi Kameyama, MD, PhD
Takayuki Enomoto, MD, PhD
Toshifumi Wakai, MD, PhD, FACS
Publikationsdatum
05.04.2021
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2021
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-021-09899-8

Weitere Artikel der Ausgabe 12/2021

Annals of Surgical Oncology 12/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.